Agilent Array Q3 Sales Rise 20 Percent Amid Decline in Bio-Analytical Revenue | GenomeWeb

By Justin Petrone

Demand for Agilent Technologies' array products "remains strong," and the company posted a 20-percent rise in array revenue during its third fiscal quarter, Agilent said this week.

The results were in contrast to poor performance in the firm’s Bio-analytical segment, whose revenue during the period fell 8 percent year over year, while company-wide receipts fell 27 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.